Aldeyra Therapeutics (ALDX) Share-based Compensation (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Share-based Compensation of -$987554.0 for Q1 2026, down 117.05% on a QoQ basis from $5.8 million in Q4 2025, and down 144.4% year-over-year from $2.2 million in Q1 2025.
Aldeyra Therapeutics (ALDX) Share-based Compensation (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Share-based Compensation history runs 14 years deep, the most recent figure standing at -$987554.0 for Q1 2026.
- Quarterly Share-based Compensation fell 144.4% year-over-year to -$987554.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 16.47% YoY) and the FY2025 annual result came in at $6.1 million, down 23.6% from the prior year.
- Share-based Compensation was -$987554.0 for Q1 2026 at Aldeyra Therapeutics, down from $5.8 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.8 million in Q4 2025 and bottomed at -$6.0 million in Q4 2023.
- A 5-year average of $1.5 million and a median of $1.6 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation slumped 313.38% — and 2025, when it jumped 358.42%.
- Aldeyra Therapeutics' Share-based Compensation stood at $2.8 million in 2022, then slumped by 313.38% to -$6.0 million in 2023, then jumped by 120.99% to $1.3 million in 2024, then soared by 358.42% to $5.8 million in 2025, then plunged by 117.05% to -$987554.0 in 2026.
- Business Quant data shows ALDX's Share-based Compensation at -$987554.0 in Q1 2026, $5.8 million in Q4 2025, and $900000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 305,000.00 |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | 87.30 Mn |
| 10 | Aldeyra Therapeutics | 95.35 Mn | 95.35 Mn | - | -987,554.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -987,554.00 |
| Mar 31, 2026 | -987,554.00 |
| Dec 31, 2025 | 5.79 Mn |
| Dec 31, 2025 | 5.79 Mn |
| Sep 30, 2025 | 900,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 196,564.00 |
| Jun 30, 2025 | 196,564.00 |
| Mar 31, 2025 | 2.22 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | -6.02 Mn |
| Dec 31, 2023 | -6.02 Mn |